Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BC923
- Development stage
- Unknown
- Lead developer
- Youjia Biopharmaceutical Technology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
BC923 (also known as YJH-014) is a small interfering RNA (siRNA) therapeutic developed for the treatment of hypertension. It is designed to target angiotensinogen (AGT) mRNA in the liver, thereby silencing AGT expression at its source and inhibiting the renin-angiotensin-aldosterone system (RAAS) pathway. By reducing AGT levels, BC923 aims to provide sustained and stable blood pressure reduction with potentially extended dosing intervals. The drug was co-developed through a strategic partnership between Youjia (Hangzhou) Biomedical Technology Co., Ltd. (Youjia Bio) and Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. (Buchang Bio), with its Investigational New Drug (IND) application accepted by the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) in August 2026 and approved in October 2026.
- Other names
- BC-923BC923BC 923BC923 InjectionBC-923 InjectionBC 923 InjectionYJH-014 InjectionYJH014 InjectionYJH 014 Injection
02
Targets
AGT (O6-methylguanine-DNA methyltransferase)
Beyond the preview
Go deeper on BC923.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BC923.